Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.

Journal article

Peto L. et al, (2024), Lancet, 403, 1339 - 1340

Community involvement in an outbreak - One year on for mpox.

Journal article

Cheyne A. et al, (2023), Clin Infect Dis

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Journal article

RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

Journal article

RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507

Randomised controlled trials for mpox in endemic countries.

Journal article

Rojek A. et al, (2023), Lancet Infect Dis

Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.

Journal article

Peto L. et al, (2022), Adv Biol Regul

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Journal article

RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151

Load More